King's College London

Research portal

Design of clinically useful macromolecular iron chelators

Research output: Contribution to journalLiterature review

Tao Zhou, Guenther Winkelmann, Zhi-Yuan Dai, Robert C. Hider

Original languageEnglish
Pages (from-to)893 - 903
Number of pages11
JournalJournal of Pharmacy and Pharmacology
Volume63
Issue number7
DOIs
Publication statusPublished - Jul 2011

King's Authors

Research Groups

  • King's College London

Abstract

Objectives In recent years, macromolecular iron chelators have received increasing attention as human therapeutic agents. The objectives of this article are: one, to discuss the factors which should be considered when designing iron binding macromolecules as human therapeutic agents, and two, to report recent achievements in the design and synthesis of appropriate macromolecular chelators that have resulted in the production of a number of agents with therapeutic potential. Key findings Macromolecular drugs exhibit unique pharmaceutical properties that are fundamentally different from their traditional small-molecule counterparts. By virtue of their high-molecular-weight characteristics, many are confined to extracellular compartments, for instance, the serum and the gastrointestinal tract. In addition, they have potential for topical administration. Consequently, these macromolecular drugs are free from many of the toxic effects that are associated with their low-molecular-weight analogues. Summary The design and synthesis of macromolecular iron chelators provides a novel aspect to chelation therapy. 3-Hydroxypyridin-4-one hexadentate-based macromolecular chelators have considerable potential for the development of new treatments for iron overload and for topical treatment of infection.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454